BRAF and melanoma: In our cohort, patients with BRAF wildtype melanoma brain metastases demonstrated significantly improved median OS with postoperative checkpoint inhibition (with immunotherapy, undefined; without immunotherapy, 13.0 months [range, 1.1-61.7 months]; P = .001; log-rank test) (Figure 4A), while patients with BRAF V600 variant melanoma brain metastases did not have improved median OS (with immunotherapy, 9.8 months [range, 2.9-39.8 months]; without immunotherapy, 9.5 months [range, 2.5-67.2 months]; P = .81; log-rank test) (Figure 4B).